Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESTIT study of eltrombopag as second-line therapy in adult primary immune thrombocytopenia
2015-001327-23Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in immune thrombocytopenia (ITP), sponsored by GIMEMA. Primary endpoint: Long-term sustained response after eltrombopag discontinuation. Started Apr 2015; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2015-001327-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001327-23.